Akeso, Inc. (FRA:4RY)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.28B -22.0% |
| Revenue (ttm) | 444.61M +37.4% |
| Net Income | -124.63M |
| EPS | -0.14 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 124.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 9.80 |
| Previous Close | 9.50 |
| Day's Range | 9.74 - 9.80 |
| 52-Week Range | 9.16 - 16.41 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About Akeso
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndr... [Read more]
Financial Performance
In 2025, Akeso's revenue was 3.06 billion, an increase of 43.90% compared to the previous year's 2.12 billion. Losses were -1.11 billion, 116.3% more than in 2024.
Financial numbers in CNY Financial StatementsNews
Akeso announces Phase III HARMONi-GI1 trial met its primary endpoint
Akeso (AKESF) announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial. The study evaluated first-in-class ivonescim...
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. jointly announced an international multicenter Phase II clinical stud...
Akeso Doses First Patient In Phase 3 Cadonilimab Study For MSI-H Colon Cancer
(RTTNews) - Akeso, Inc. (9926.HK,AKESF) announced that the first patient has been dosed in a Phase III clinical study, COMPASSION-40/AK104-313, evaluating cadonilimab, its investigational PD-1/CTLA-4 ...
Akeso announces first patient dosed in Phase III study of cadonilimab
Akeso (AKESF) announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvan...
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s glob...
Akeso Enrolls First Patient In Phase 3 Cadonilimab Head-To-Head Gastric Cancer Trial
(RTTNews) - Akeso, Inc. (9926.HK), a biopharmaceutical company, announced that it has enrolled the first patient in COMPASSION-37 (AK104-311), a phase 3 trial evaluating Cadonilimab as first-line trea...
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter P...
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
Chinese biopharma stocks advanced Monday, with Innovent Biologics jumping 7% and Akeso up 8% after a report that the U.S. may allow most drug licensing deals with Chinese firms to continue. The propo...
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targetin...
Big Pharma Is Pouring Billions Into China's Biotechs
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrationa...
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales r...
Akeso Earnings release: H1 2026
Akeso released its H1 2026 earnings on August 27, 2026, summarizing the period's financial results.
Akeso Quarterly report: H1 2026
Akeso has published its H1 2026 quarterly earnings report on August 27, 2026.
Akeso Slides: H1 2026
Akeso has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 27, 2026.
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D...
Summit says Akeso receives marketing authorization in China for ivonescimab
Summit Therapeutics (SMMT) noted that, on August 12, its partner Akeso (AKESF) announced receipt of marketing authorization in China from the National Medical Products Administration for the use of iv...
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1...
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) t...
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (...
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internall...
An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial
An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk o...
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of...